The U.S. Patent Office published Citius Pharmaceuticals' patent application for enhanced stability of antimicrobial solutions for locking central venous catheters.
According to Citius, a developer of adjunctive cancer care and critical care drug products, the patent invention overcomes limitations in mixing antimicrobial solutions. The company holds an exclusive worldwide license for the technology, which will be put toward its Mino-Lok solution.
"The stability of the Mino-Lok solution post mixing was limited to a time period of about 24 hours prior to use," Citius Pharmaceuticals President and CEO Myron Holubiak said in a statement. "We recognized that it would be beneficial for product acceptance and utility if improvement in the post-mix stability could be achieved; this would enable standard pharmacy process to be employed in the delivery of Mino-Lok to the patient, and would allow for several days storage of ready-to-use Mino-Lok."
Holubiak said aside from also offering greater intellectual property protection if the patent is granted, the post-mix stability of Mino-Lok is important to the potential world market for the product.
"Citius is committed to developing Mino-Lok as a cost saving therapy in all countries, as we believe Mino-Lok should find receptive markets worldwide," he said.
Alerts Sign-up